• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sichenzia Ross Ference Carmel LLP Achieves Firm Record Advising on Over 170 Transactions Totaling Over $14 Billion in 2025

    1/20/26 8:00:00 AM ET
    $EMIS
    $NCRA
    $SOUL
    $STEX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Farming/Seeds/Milling
    Consumer Staples
    Get the next $EMIS alert in real time by email

    NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Sichenzia Ross Ference Carmel LLP ("SRFC") reported that in 2025 it advised on over 170 announced transactions, with the total value of these transactions exceeding $14 billion, far surpassing the firm's strong performance in 2024. The transactions, on behalf of various market participants, such as issuers, underwriters and investors, included initial public offerings, secondary public offerings, registered direct offerings, private placements, mergers, acquisitions and cryptocurrency transactions.

    In October of 2025, for the fifth consecutive quarter, SRFC was ranked first in the nation for issuer counsel among securities law firms in PlacementTracker's PIPE and Private Placement Markets League Tables for Q3 2025.

    Notable transaction highlights from 2025 include the following representations:

    • Soulpower Acquisition Corporation (NYSE:SOUL) in a definitive business combination agreement with SWB LLC, valued at approximately $8.1 billion.



    • Streamex Corp. (formerly BioSig Technologies, Inc.) (NASDAQ:STEX) in its $1.1 billion growth financing arrangements.



    • Sharps Technology, Inc. (NASDAQ:STSS, STSSW)) in a $400 million private placement.



    • Nocera, Inc. (NASDAQ:NCRA) in a private placement of up to $300 million.



    • Emmis Acquisition Corp. (NASDAQ:EMIS, EMISR)) in its $100 million SPAC initial public offering.



    "The incredible results of our firm's work this past year impresses but doesn't surprise me or any other attorney on this team. Each year, SRFC grows and expands its client base by providing exemplary services and doing right by our clients. It's only natural that more and more companies would take notice of our results and want to retain us as well," said Gregory Sichenzia, founding partner at SRFC. "Prominent entrepreneurs and business leaders want their legal needs handled by the industry's best, and when it comes to complex securities transactions, there's no one better than SRFC. I expect our team to build upon this incredible momentum in 2026."

    "Our firm has been building to this level of success for a while now, as our growing team of talented attorneys have advised on transactions of all kinds across a vast spectrum of industries," said Ross Carmel, named partner at SRFC. "We want to thank our clients, partners and colleagues for an incredible year in 2025 and cannot wait to see continued success throughout this year."

    A full list of the firm's transactions can be found here.

    About Sichenzia Ross Ference Carmel LLP

    SRFC is a nationally recognized law firm of approximately 70 attorneys with corporate, securities, litigation, trusts and estates and tax practices, serving clients from all over the world. Our mission is to solve our clients' most complicated legal problems and achieve their business goals in an expeditious, commercial and innovative manner.

    www.srfc.law

    Media Contact:

    [email protected]

    This press release may constitute attorney advertising. Prior results do not guarantee a similar outcome. The information in this press release is for general informational purposes only and should not be construed as legal advice or a substitute for obtaining legal advice from an attorney.



    Primary Logo

    Get the next $EMIS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EMIS
    $NCRA
    $SOUL
    $STEX

    CompanyDatePrice TargetRatingAnalyst
    Streamex Corp.
    $STEX
    11/25/2025$12.00Buy
    Needham
    More analyst ratings

    $EMIS
    $NCRA
    $SOUL
    $STEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Lekstrom Morgan Lee bought $50,000 worth of shares (20,000 units at $2.50) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/18/26 1:41:34 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Falconx Holdings Ltd sold $1,490,755 worth of shares (769,320 units at $1.94) and exercised 461,538 in-the-money shares at a strike of $0.00 (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    2/13/26 4:45:04 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    New insider Falconx Holdings Ltd claimed ownership of 769,230 shares (SEC Form 3)

    3 - Sharps Technology Inc. (0001737995) (Issuer)

    2/13/26 4:10:05 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $EMIS
    $NCRA
    $SOUL
    $STEX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Emmis Acquisition Corp.

    SCHEDULE 13G/A - Emmis Acquisition Corp. (0002075816) (Subject)

    2/13/26 6:00:03 PM ET
    $EMIS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Streamex Corp. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Streamex Corp. (0001530766) (Filer)

    2/13/26 5:09:54 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Streamex Corp.

    424B5 - Streamex Corp. (0001530766) (Filer)

    2/13/26 5:04:45 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EMIS
    $NCRA
    $SOUL
    $STEX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Streamex Exchange Corporation with a new price target

    Needham initiated coverage of Streamex Exchange Corporation with a rating of Buy and set a new price target of $12.00

    11/25/25 7:59:34 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EMIS
    $NCRA
    $SOUL
    $STEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Lekstrom Morgan Lee bought $50,000 worth of shares (20,000 units at $2.50) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/18/26 1:41:34 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Giustra Frank bought $317,000 worth of shares (100,000 units at $3.17) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/4/26 7:04:10 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Lekstrom Morgan Lee bought $71,910 worth of shares (23,500 units at $3.06) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/3/26 11:32:53 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EMIS
    $NCRA
    $SOUL
    $STEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Streamex Announces Official Launch Date of GLDY, a Yield Bearing Gold-Backed Tokenized Security

    WINTER PARK, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex") (NASDAQ:STEX), a commodity focused real-world asset tokenization company, today announced the official launch date of GLDY, a gold-backed, tokenized security designed to provide exposure to physical gold while generating yield. GLDY is scheduled to launch on February 25, 2026. Henry McPhie, Co-Founder & Chief Executive Officer of Streamex, said: "For decades, investors have accepted that holding gold comes with a cost, whether through storage, insurance, or ETF management fees. GLDY fundamentally changes that equation. After more than three and a half years of building the infrastructure, we've created a prod

    2/18/26 7:31:02 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Co-Founder & Executive Chairman Provides Corporate Update

    WINTER PARK, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), an institutional-grade digital asset and real-world asset tokenization company, today provided a corporate update from its Co-Founder & Executive Chairman, Morgan Lekstrom, highlighting recent strategic progress, balance sheet strength, insider alignment, preparations for the upcoming launch of GLDY, and the 2026 strategic roadmap. Executive Chairman Commentary Morgan Lekstrom, Co-Founder & Executive Chairman of Streamex, commented: "Streamex now has a strong, well-capitalized foundation as we move toward the launch of GLDY. The Company is supported by an experienced leadersh

    2/10/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Appoints Morgan Lekstrom as Executive Chairman, and Announces Completed Repayment of Convertible Debenture and Cancellation of SEPA

    WINTER PARK, Fla., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced that its Co-Founder and Chairman, Morgan Lekstrom, has been named Executive Chairman and will join the executive leadership team. The Company has also announced that the previously entered into Secured Convertible Debentures with YA II PN, LTD., a Cayman Islands exempt limited company ("Yorkville" or "Holder") have been fully repaid and the Standby Equity Purchase Agreement (the "SEPA") previously entered into with Yorkville has been cancelled. "I am honoured and excited to step int

    2/9/26 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EMIS
    $NCRA
    $SOUL
    $STEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

    SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    11/13/24 4:50:17 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

    SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    10/9/24 9:01:14 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Sharps Technology Inc.

    SC 13G - Sharps Technology Inc. (0001737995) (Subject)

    2/14/24 11:14:11 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $EMIS
    $NCRA
    $SOUL
    $STEX
    Leadership Updates

    Live Leadership Updates

    View All

    Streamex Corp. (NASDAQ: STEX) Appoints Morgan Lekstrom as Executive Chairman, and Announces Completed Repayment of Convertible Debenture and Cancellation of SEPA

    WINTER PARK, Fla., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced that its Co-Founder and Chairman, Morgan Lekstrom, has been named Executive Chairman and will join the executive leadership team. The Company has also announced that the previously entered into Secured Convertible Debentures with YA II PN, LTD., a Cayman Islands exempt limited company ("Yorkville" or "Holder") have been fully repaid and the Standby Equity Purchase Agreement (the "SEPA") previously entered into with Yorkville has been cancelled. "I am honoured and excited to step int

    2/9/26 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Appoints Anthony Marciano, Clinical Professor of Finance at NYU Stern to Board of Directors

    WINTER PARK, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced the appointment of Anthony Marciano, Clinical Professor of Finance at NYU Stern School of Business, to its Board of Directors. In this role, Marciano will bring deep expertise in corporate finance, mergers and acquisitions, and financial markets to strengthen Streamex's governance and strategic capital markets initiatives. He is joining as an independent director. "Anthony is an outstanding addition to our Board. His deep-rooted expertise in institutional finance, combined with a stro

    2/4/26 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Joins Solana Policy Institute in the Project Open Coalition to Advance Regulated On-Chain Trading of Real-World Assets, Including GLDY

    LOS ANGELES, Dec. 10, 2025 (GLOBE NEWSWIRE) --  Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization of real-world assets, today announced it has joined Project Open, a landmark initiative working to establish a regulated framework for the issuance and trading of securities on public blockchains. The effort aims to unlock billions in traditional asset value through 24/7 trading, instant settlement, lower costs, and enhanced transparency for all real-world assets, while keeping the United States competitive in financial innovation. Streamex joins Solana Policy Institute united to drive the next era of compliant digital market infrastructur

    12/10/25 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EMIS
    $NCRA
    $SOUL
    $STEX
    Financials

    Live finance-specific insights

    View All

    Streamex Corp. (NASDAQ: STEX) Acquires 9.9% Strategic Equity Stake in Royalty and Streaming Firm Empress Royalty Corp. Through a Premium Priced Share-for-Share Transaction at US$5.00 STEX with a Leading Institutional Investment Firm

    LOS ANGELES, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and real-world asset infrastructure, today announced that it has acquired a 9.9% equity interest in Empress Royalty Corp. ("Empress") (TSXV:EMPR) through a strategic share purchase from Terra Capital Natural Resources Fund Pty Ltd. ("Terra Capital"), a prominent institutional investor. Under the executed Share Purchase Agreement, Streamex acquired 12,671,297 common shares of Empress in exchange for 2,443,750 restricted common shares of Streamex at a US$5.00 STEX share price, representing a premium to the current market price of STEX and an

    12/11/25 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Announces Launch of $100,000,000 USD GLDY Pre-Sale – A Gold-Backed Yield Generating Stablecoin Offering Institutional Yield on Physical Gold Bullion

    The launch of Streamex's $100 million USD GLDY pre-sale marks a historic opportunity for gold investors. Investing in gold is no longer just a static store of value, Streamex, through GLDY has created a yield-generating, institutional grade asset designed to offer both spot gold exposure and yield paid in additional ounces of physical gold bullion.  Key Highlights Gold Price Exposure and Gold-Denominated Distributions: GLDY is designed to combine audited physical bullion holdings with yield from institutionally managed gold leases sourced through Monetary Metals. GLDY seeks to provide exposure to the price of gold while targeting periodic distributions paid in additional ounces of gold.Rev

    11/10/25 8:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Sharps Technology, Inc. Acquires Over 2 Million SOL, the Native Asset of Solana, the Fastest and Most Used Public Blockchain

    NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Sharps Technology, Inc. (the "Company" or "Sharps Technology") (Nasdaq: "STSS" and "STSSW") today announced its first acquisition of Solana ("SOL") tokens as part of its digital asset treasury strategy under which the principal holding will be SOL, the native digital asset of the Solana blockchain. Funded from the Company's recent PIPE equity raise, Sharps Technology now holds over 2 million SOL, creating a SOL treasury currently valued north of $400M. Sharps Technology intends to provide regular updates on its SOL holdings and performan

    9/2/25 7:00:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care